Dr. Reddy's Laboratories, a key Indian pharmaceutical player, has been banned from China's large-scale drug procurement initiatives following a critical inspection. The probe by China's NMPA revealed significant lapses in the manufacturing process of the company's ADHD medication Atomoxetine Hydrochloride. This has led to a suspension lasting until 2026, with Dr. Reddy's assessing the financial impact.